<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>7667</number>
    <updateDate>2022-12-29T23:48:32Z</updateDate>
    <updateDateIncludingText>2022-12-29T23:48:32Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2022-05-06</introducedDate>
    <congress>117</congress>
    <constitutionalAuthorityStatementText>
      <![CDATA[<pre>[Congressional Record Volume 168, Number 76 (Friday, May 6, 2022)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Ms. ESHOO:H.R. 7667.Congress has the power to enact this legislation pursuantto the following:Under Article I, Section 8, Clause 3: [The Congress shallhave Power] To regulate Commerce with foreign Nations, andamong the several States, and with the Indian Tribes.[Page H4723]</pre>]]>
    </constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Reported by</name>
                <date>2022-05-11T17:49:44Z</date>
              </item>
              <item>
                <name>Markup by</name>
                <date>2022-05-11T17:45:26Z</date>
              </item>
              <item>
                <name>Referred to</name>
                <date>2022-05-09T17:41:13Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2022-06-07T18:38:19Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2022-05-18T21:03:15Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2022-05-06T14:02:40Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <committeeReports>
      <committeeReport>
        <citation>H. Rept. 117-348</citation>
      </committeeReport>
    </committeeReports>
    <relatedBills>
      <item>
        <title>FDA Modernization Act of 2021</title>
        <congress>117</congress>
        <number>2565</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2021-04-16</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Helping Experts Accelerate Rare Treatments Act of 2022</title>
        <congress>117</congress>
        <number>6888</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-02</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.</title>
        <congress>117</congress>
        <number>6980</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-09</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>INSPECTIONS Act</title>
        <congress>117</congress>
        <number>7006</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-10</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Increasing Transparency in Generic Drug Applications Act of 2022</title>
        <congress>117</congress>
        <number>7032</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-10</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Biologics Market Transparency Act of 2022</title>
        <congress>117</congress>
        <number>7035</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-10</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>PATCH Act of 2022</title>
        <congress>117</congress>
        <number>7084</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-16</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.</title>
        <congress>117</congress>
        <number>7649</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-05-03</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <congress>117</congress>
        <number>7658</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-05-03</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDA Modernization Act of 2021</title>
        <congress>117</congress>
        <number>2952</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-10-07</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>PATCH Act</title>
        <congress>117</congress>
        <number>3983</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-03-31</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <congress>117</congress>
        <number>4152</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-05</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>GAIN TOOLS Act of 2022</title>
        <congress>117</congress>
        <number>3478</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-01-11</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Drug Manufacturing Innovation Act of 2022</title>
        <congress>117</congress>
        <number>6988</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-09</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Enhanced Access to Affordable Medicines Act of 2022</title>
        <congress>117</congress>
        <number>4351</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-06-06</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Biologics Market Transparency Act of 2022</title>
        <congress>117</congress>
        <number>4302</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-25</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>CLEAR Act</title>
        <congress>117</congress>
        <number>4333</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-26</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Increasing Transparency in Generic Drug Applications Act</title>
        <congress>117</congress>
        <number>4338</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-26</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDASRA Act of 2022</title>
        <congress>117</congress>
        <number>4535</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-07-14</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Pre-Approval Information Exchange Act of 2022</title>
        <congress>117</congress>
        <number>9297</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-11-16</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2022-06-09</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Received in the Senate.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2022-06-08</actionDate>
        <actionTime>20:31:14</actionTime>
        <text>Motion to reconsider laid on the table Agreed to without objection.</text>
        <type>Floor</type>
        <actionCode>H38310</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-08</actionDate>
        <actionTime>20:31:13</actionTime>
        <text>On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254). (text: 06/07/2022 CR H5298-5319)</text>
        <type>Floor</type>
        <actionCode>H37300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <recordedVotes>
          <recordedVote>
            <rollNumber>254</rollNumber>
            <url>https://clerk.house.gov/evs/2022/roll254.xml</url>
            <chamber>House</chamber>
            <congress>117</congress>
            <date>2022-06-09T00:31:13Z</date>
            <sessionNumber>2</sessionNumber>
          </recordedVote>
        </recordedVotes>
      </item>
      <item>
        <actionDate>2022-06-08</actionDate>
        <actionTime>20:31:13</actionTime>
        <text>Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).</text>
        <type>Floor</type>
        <actionCode>8000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <recordedVotes>
          <recordedVote>
            <rollNumber>254</rollNumber>
            <url>https://clerk.house.gov/evs/2022/roll254.xml</url>
            <chamber>House</chamber>
            <congress>117</congress>
            <date>2022-06-09T00:31:13Z</date>
            <sessionNumber>2</sessionNumber>
          </recordedVote>
        </recordedVotes>
      </item>
      <item>
        <actionDate>2022-06-08</actionDate>
        <actionTime>20:23:21</actionTime>
        <text>Considered as unfinished business. (consideration: CR H5402-5403)</text>
        <type>Floor</type>
        <actionCode>H30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <actionTime>18:38:20</actionTime>
        <text>At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.</text>
        <type>Floor</type>
        <actionCode>H37220</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <actionTime>18:18:18</actionTime>
        <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 7667.</text>
        <type>Floor</type>
        <actionCode>H8D000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <actionTime>18:18:16</actionTime>
        <text>Considered under suspension of the rules. (consideration: CR H5298-5321)</text>
        <type>Floor</type>
        <actionCode>H30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <actionTime>18:17:55</actionTime>
        <text>Mr. Pallone moved to suspend the rules and pass the bill, as amended.</text>
        <type>Floor</type>
        <actionCode>H30300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <text>Placed on the Union Calendar, Calendar No. 262.</text>
        <type>Calendars</type>
        <actionCode>H12410</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <calendarNumber>
          <calendar>U00262</calendar>
        </calendarNumber>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.</text>
        <type>Committee</type>
        <actionCode>H12200</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-06-07</actionDate>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.</text>
        <type>Committee</type>
        <actionCode>5000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-05-18</actionDate>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Ordered to be Reported (Amended) by the Yeas and Nays: 55 - 0.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-18</actionDate>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Committee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-11</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-11</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Subcommittee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-09</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-06</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-05-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-05-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>E000215</bioguideId>
        <fullName>Rep. Eshoo, Anna G. [D-CA-18]</fullName>
        <firstName>ANNA</firstName>
        <lastName>ESHOO</lastName>
        <party>D</party>
        <state>CA</state>
        <identifiers>
          <bioguideId>E000215</bioguideId>
        </identifiers>
        <middleName>G.</middleName>
        <district>18</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>G000558</bioguideId>
        <fullName>Rep. Guthrie, Brett [R-KY-2]</fullName>
        <firstName>Brett</firstName>
        <lastName>Guthrie</lastName>
        <party>R</party>
        <state>KY</state>
        <identifiers>
          <bioguideId>G000558</bioguideId>
        </identifiers>
        <district>2</district>
        <sponsorshipDate>2022-05-06</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>P000034</bioguideId>
        <fullName>Rep. Pallone, Frank, Jr. [D-NJ-6]</fullName>
        <firstName>FRANK</firstName>
        <lastName>PALLONE</lastName>
        <party>D</party>
        <state>NJ</state>
        <identifiers>
          <bioguideId>P000034</bioguideId>
        </identifiers>
        <district>6</district>
        <sponsorshipDate>2022-05-06</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001159</bioguideId>
        <fullName>Rep. McMorris Rodgers, Cathy [R-WA-5]</fullName>
        <firstName>Cathy</firstName>
        <lastName>Rodgers</lastName>
        <party>R</party>
        <state>WA</state>
        <identifiers>
          <bioguideId>M001159</bioguideId>
        </identifiers>
        <middleName>McMorris</middleName>
        <district>5</district>
        <sponsorshipDate>2022-05-06</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2022-06-06T20:07:00Z</pubDate>
        <title>Estimated Budgetary Effects of H.R. 7667, the Food and Drug Amendments of 2022 Act</title>
        <url>https://www.cbo.gov/publication/58183</url>
      </item>
    </cboCostEstimates>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Advanced technology and technological innovations</name>
        </item>
        <item>
          <name>Advisory bodies</name>
        </item>
        <item>
          <name>Animal protection and human-animal relationships</name>
        </item>
        <item>
          <name>Blood and blood diseases</name>
        </item>
        <item>
          <name>Business records</name>
        </item>
        <item>
          <name>Cardiovascular and respiratory health</name>
        </item>
        <item>
          <name>Child health</name>
        </item>
        <item>
          <name>Computer security and identity theft</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Criminal investigation, prosecution, interrogation</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Emergency medical services and trauma care</name>
        </item>
        <item>
          <name>Employee hiring</name>
        </item>
        <item>
          <name>Evidence and witnesses</name>
        </item>
        <item>
          <name>Executive agency funding and structure</name>
        </item>
        <item>
          <name>Food and Drug Administration (FDA)</name>
        </item>
        <item>
          <name>Genetics</name>
        </item>
        <item>
          <name>Government employee pay, benefits, personnel management</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health care coverage and access</name>
        </item>
        <item>
          <name>Health programs administration and funding</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Industrial facilities</name>
        </item>
        <item>
          <name>Infectious and parasitic diseases</name>
        </item>
        <item>
          <name>Inflation and prices</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Marketing and advertising</name>
        </item>
        <item>
          <name>Medical research</name>
        </item>
        <item>
          <name>Minority health</name>
        </item>
        <item>
          <name>Musculoskeletal and skin diseases</name>
        </item>
        <item>
          <name>Organ and tissue donation and transplantation</name>
        </item>
        <item>
          <name>Performance measurement</name>
        </item>
        <item>
          <name>Photography and imaging</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Product development and innovation</name>
        </item>
        <item>
          <name>Public participation and lobbying</name>
        </item>
        <item>
          <name>Public-private cooperation</name>
        </item>
        <item>
          <name>Radiation</name>
        </item>
        <item>
          <name>Research and development</name>
        </item>
        <item>
          <name>Small business</name>
        </item>
        <item>
          <name>User charges and fees</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2022-05-06</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2022-06-07T20:51:35Z</updateDate>
        <text>
          <![CDATA[ <p><b>Food and Drug Amendments of 2022</b></p> <p>This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.</p> <p>Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.</p> <p>The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.</p> <p>In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). </p> <p>The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.</p>]]>
        </text>
      </summary>
      <summary>
        <versionCode>07</versionCode>
        <actionDate>2022-06-07</actionDate>
        <actionDesc>Reported to House</actionDesc>
        <updateDate>2022-06-16T23:34:36Z</updateDate>
        <text>
          <![CDATA[ <p><b>Food and Drug Amendments of 2022</b></p> <p>This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.</p> <p>Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.</p> <p>The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.</p> <p>In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). </p> <p>The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.</p>]]>
        </text>
      </summary>
      <summary>
        <versionCode>53</versionCode>
        <actionDate>2022-06-08</actionDate>
        <actionDesc>Passed House</actionDesc>
        <updateDate>2022-06-25T00:31:45Z</updateDate>
        <text>
          <![CDATA[ <p><b>Food and Drug Amendments of 2022</b></p> <p>This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.</p> <p>Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.</p> <p>The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.</p> <p>In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). </p> <p>The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.</p>]]>
        </text>
      </summary>
    </summaries>
    <title>Food and Drug Amendments of 2022</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Food and Drug Amendments of 2022</title>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House for portions of this bill</titleType>
        <title>Biosimilar User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House for portions of this bill</titleType>
        <title>Generic Drug User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House for portions of this bill</titleType>
        <title>Prescription Drug User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House</titleType>
        <title>Food and Drug Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House for portions of this bill</titleType>
        <title>Medical Device User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House</titleType>
        <title>Food and Drug Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House for portions of this bill</titleType>
        <title>Biosimilar User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House for portions of this bill</titleType>
        <title>Generic Drug User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House for portions of this bill</titleType>
        <title>Medical Device User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House for portions of this bill</titleType>
        <title>Prescription Drug User Fee Amendments of 2022</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Medical Device User Fee Amendments of 2022</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Prescription Drug User Fee Amendments of 2022</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Generic Drug User Fee Amendments of 2022</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Biosimilar User Fee Amendments of 2022</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Food and Drug Amendments of 2022</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Engrossed in House</type>
        <date>2022-06-08T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr7667eh/xml/BILLS-117hr7667eh.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Reported in House</type>
        <date>2022-06-07T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr7667rh/xml/BILLS-117hr7667rh.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in House</type>
        <date>2022-05-06T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr7667ih/xml/BILLS-117hr7667ih.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date/>
        <formats/>
        <type/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2022-06-09</actionDate>
      <text>Received in the Senate.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
